Horn DB, Ryan DH, Kis SG, Alves B, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet 2025 Nov 20:S0140-6736(25)02165-8. doi: 10.1016/S0140-6736(25)02165.
PMID: 41275875